Literature DB >> 15094933

Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.

Shosaku Nomura1, Akira Shouzu, Seitaro Omoto, Mitsushige Nishikawa, Toshiji Iwasaka.   

Abstract

Monocyte-derived microparticles play an important role in the pathogenesis of diabetic vasculopathy, and angiotensin II receptor blocker and statin have been shown to have a beneficial effect on the angiopathies of hypertension and hyperglycemia in patients with type 2 diabetes mellitus. However, the interaction between angiotensin II receptor blocker and statin, and monocyte-derived microparticles in atherosclerosis is poorly understood. The effects of losartan and simvastatin on circulating concentrations of monocyte-derived microparticles, chemokines, and soluble adhesion markers were studied in hypertensive patients with or without type 2 diabetes mellitus. Monocyte-derived microparticles were measured by flow cytometry, and levels of serum chemokines (MCP-1 and RANTES) and soluble adhesion markers (sP-selectin and sVCAM-1) were measured by enzyme-linked immunosorbent assay. Losartan decreased both the systolic and diastolic blood pressure in hypertensive patients with and without type 2 diabetes mellitus. The concentrations of monocyte-derived microparticles, chemokines, and soluble adhesion molecules were higher in hypertensive patients who also had type 2 diabetes mellitus vs. those who did not. The administration of angiotensin II receptor blocker decreased the circulating concentration of all these markers. In addition, all markers were decreased by combination therapy, and monocyte-derived microparticles were decreased more with combination therapy with losartan and simvastatin than monotherapy with losartan. The administration of angiotensin II receptor blocker inhibited monocyte-derived microparticle generation and suggests that angiotensin II is intimately related to vascular changes that occur in type 2 diabetes mellitus. Combination therapy with a statin and angiotensin II receptor blocker might be valuable as anti-atherosclerotic therapy in patients with type 2 diabetes mellitus and nephropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15094933     DOI: 10.1177/107602960401000203

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  19 in total

Review 1.  The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases.

Authors:  Paolo Puddu; Giovanni M Puddu; Eleonora Cravero; Silvia Muscari; Antonio Muscari
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

Review 2.  Microparticles and cardiovascular diseases.

Authors:  Christos Voukalis; Eduard Shantsila; Gregory Y H Lip
Journal:  Ann Med       Date:  2019-06-17       Impact factor: 4.709

Review 3.  Extracellular vesicles in coronary artery disease.

Authors:  Chantal M Boulanger; Xavier Loyer; Pierre-Emmanuel Rautou; Nicolas Amabile
Journal:  Nat Rev Cardiol       Date:  2017-02-02       Impact factor: 32.419

4.  Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study.

Authors:  Nicolas Amabile; Susan Cheng; Jean Marie Renard; Martin G Larson; Anahita Ghorbani; Elizabeth McCabe; Gabriel Griffin; Coralie Guerin; Jennifer E Ho; Stanley Y Shaw; Kenneth S Cohen; Ramachandran S Vasan; Alain Tedgui; Chantal M Boulanger; Thomas J Wang
Journal:  Eur Heart J       Date:  2014-04-16       Impact factor: 29.983

Review 5.  Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.

Authors:  Ying Wang; Li-ming Chen; Ming-lin Liu
Journal:  Acta Pharmacol Sin       Date:  2014-03-10       Impact factor: 6.150

Review 6.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

7.  Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population.

Authors:  Anne M Curtis; Lifeng Zhang; Elizabeth Medenilla; Ming Gui; Patrick F Wilkinson; Erding Hu; Jay Giri; Vijay Doraiswamy; Sampath Gunda; Mark E Burgert; Jonni S Moore; Jay M Edelberg; Emile R Mohler
Journal:  Cytometry B Clin Cytom       Date:  2010-06-11       Impact factor: 3.058

Review 8.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

9.  Vascular inflammation and endothelial dysfunction in experimental hypertension.

Authors:  Carmine Savoia; Lidia Sada; Luigi Zezza; Lorenzo Pucci; Francesco Maria Lauri; Alberto Befani; Alessandro Alonzo; Massimo Volpe
Journal:  Int J Hypertens       Date:  2011-09-11       Impact factor: 2.420

10.  Elevated levels of procoagulant plasma microvesicles in dialysis patients.

Authors:  James O Burton; Hassan A Hamali; Ruchir Singh; Nima Abbasian; Ruth Parsons; Amit K Patel; Alison H Goodall; Nigel J Brunskill
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.